How Can Progress Toward Ending the Human Immunodeficiency Virus Epidemic in the United States Be Monitored?
HIV
estimates
incidence surveys
infections
surveillance data
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
received:
18
06
2021
pubmed:
2
12
2021
medline:
30
8
2022
entrez:
1
12
2021
Statut:
ppublish
Résumé
The plan for Ending the HIV (human immunodeficiency virus) Epidemic (EHE) in the United States aims to reduce new infections by 75% by 2025 and by 90% by 2030. For EHE to be successful, it is important to accurately measure changes in numbers of new HIV infections after 5 and 10 years (to determine whether the EHE goals have been achieved) but also over shorter timescales (to monitor progress and intensify prevention efforts if required). In this viewpoint, we aim to demonstrate why the method used to monitor progress toward the EHE goals must be carefully considered. We briefly describe and discuss different methods to estimate numbers of new HIV infections based on longitudinal cohort studies, cross-sectional incidence surveys, and routine surveillance data. We particularly focus on identifying conditions under which unadjusted and adjusted estimates based on routine surveillance data can be used to estimate changes in new HIV infections.
Identifiants
pubmed: 34849635
pii: 6440758
doi: 10.1093/cid/ciab976
pmc: PMC9403299
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-169Subventions
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Infect Dis. 2021 Mar 3;223(5):876-884
pubmed: 32663847
PLoS One. 2011;6(8):e17502
pubmed: 21826193
JMIR Public Health Surveill. 2017 Feb 03;3(1):e8
pubmed: 28159730
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
PLoS One. 2020 Apr 16;15(4):e0231766
pubmed: 32298383
HIV Med. 2018 Jan;19(1):33-41
pubmed: 28762652
J Infect Dis. 2018 Oct 20;218(11):1777-1782
pubmed: 30010965
Lancet HIV. 2017 Feb;4(2):e83-e92
pubmed: 27863998
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):395-398
pubmed: 33136735
PLoS Med. 2011 Jun;8(6):e1001045
pubmed: 21731474
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
Epidemics. 2020 Dec;33:100423
pubmed: 33285419
Lancet HIV. 2018 Nov;5(11):e629-e637
pubmed: 30343026
J Int AIDS Soc. 2019 Mar;22(3):e25246
pubmed: 30868739
MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1113-7
pubmed: 25426654
Public Health Rep. 2007;122 Suppl 1:39-47
pubmed: 17354526
Clin Infect Dis. 2017 Jul 15;65(2):324-327
pubmed: 28383649
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):3-9
pubmed: 27509244
AIDS Behav. 2020 Jul;24(7):2024-2032
pubmed: 32350773
Med Microbiol Immunol. 2019 Oct;208(5):693-702
pubmed: 30859301
PLoS One. 2018 Jun 20;13(6):e0197939
pubmed: 29924799